What is HGH 191aa?
HGH 191aa (human growth hormone, 191 amino acids) is the recombinant form of human somatropin — a single-chain protein composed of 191 amino acids with two disulfide bridges. Its sequence is identical to the growth hormone naturally produced by the anterior pituitary gland. The “191aa” designation refers to this chain length, distinguishing it from truncated fragments or non-identical analogs.
Endogenous growth hormone is secreted in pulses by somatotroph cells in the pituitary, primarily during deep sleep and after intense exercise. Production peaks during puberty and progressively declines with age — a process known as somatopause — which has made recombinant HGH a subject of ongoing research for body composition maintenance and aging-related interventions.
Mechanism of Action
Recombinant somatropin exerts its effects through two primary pathways:
Direct pathway: GH binds to the GHR (Growth Hormone Receptor) on cell surfaces, activating the JAK2-STAT5 signaling cascade. This produces direct lipolytic effects in adipose tissue, favoring fatty acid release and oxidation, while also exerting anti-insulin effects that raise peripheral blood glucose.
Indirect pathway (IGF-1): GH stimulates hepatocytes to produce and secrete IGF-1 (insulin-like growth factor 1). Circulating IGF-1 is responsible for most systemic anabolic effects: muscle protein synthesis, cell proliferation and differentiation, and longitudinal bone growth in individuals with open epiphyses.
At the tissue level, HGH promotes nitrogen retention, stimulates collagen synthesis in tendons and cartilage, and activates muscle satellite cells, facilitating repair and growth of skeletal muscle tissue.
Reconstitution and Dose Calculation
Research HGH vials are typically lyophilized (white or clear powder). Standard reconstitution involves adding 1.0 mL of bacteriostatic water (BAC water) directly against the vial wall to prevent denaturation from mechanical agitation.
Resulting concentration: 10 IU/mL ≈ 3.3 mg/mL (given that 1 IU of GH ≈ 0.33 mg)
| Desired Dose | Volume to Draw |
|---|---|
| 1 IU | 10 units (0.10 mL) on a U-100 syringe |
| 2 IU | 20 units (0.20 mL) |
| 3 IU | 30 units (0.30 mL) |
| 4 IU | 40 units (0.40 mL) |
SC (subcutaneous) injection is typically performed in the abdominal fold, rotating sites to minimize local lipodystrophy. IM (intramuscular) injection produces a faster peak with similar overall bioavailability.
Reported Research Protocols
The most documented protocols distinguish between objectives and experience levels:
Conservative protocol (beginners): 2 IU/day, typically administered fasted (before breakfast) or before sleep to potentiate the endogenous nocturnal pulse. Nighttime injection is favored in body composition protocols because it avoids postprandial insulin resistance.
Intermediate protocol: 4-6 IU/day, potentially split into two injections (AM and PM) to maintain more stable IGF-1 levels throughout the day.
Typical duration: Research cycles commonly extend from 16 to 24 weeks, as effects on body composition are gradual and require time to become appreciable.
Storage — Critical Point
Recombinant somatropin is extremely sensitive to heat and mechanical agitation. Denaturation destroys biological activity without any visible change to the solution.
- Unreconstituted lyophilized powder: Store between 2-8°C (refrigerator). DO NOT freeze the lyophilized powder — ice crystals fragment the protein structure.
- After reconstitution: Store between 2-8°C for up to 28 days. Do not shake — gently invert or roll between palms.
- Fundamental rule: If the vial was exposed to prolonged room temperature or was vigorously shaken, its biological activity may be compromised even if the liquid appears normal.
Effects Observed in Research
Researchers and users report the following effects with continued use:
- Improved body composition: reduction of visceral and subcutaneous fat, increase in lean mass
- Accelerated post-exercise recovery, particularly in connective tissues (tendons, ligaments)
- Improved deep sleep quality (deep sleep also stimulates endogenous GH, creating a positive feedback loop)
- Dermatological effects: improved skin turgor and elasticity
- Enhanced energy levels and general sense of well-being
Documented Adverse Effects
The most common adverse effects reported in clinical trials and research studies include:
- Fluid retention (peripheral edema): Particularly in extremities. Related to the antinatriuretic effect of GH. Generally reversible upon dose reduction.
- Carpal tunnel syndrome: Median nerve compression from local edema. Common at higher doses (>4 IU/day).
- Insulin resistance: GH exerts a direct anti-insulin effect and may elevate fasting blood glucose.
- Arthralgia and myalgia: Joint and muscle pain, especially at protocol initiation.
- Paresthesias: Tingling or numbness sensations, usually in the hands and feet.
- Mild gynecomastia: In prolonged protocols, possibly related to IGF-1 aromatization.
Regulatory Framework
Somatropin with approved medical indications (GH deficiency in adults and children, Turner syndrome, Prader-Willi syndrome, pediatric chronic kidney disease, among others) requires a medical prescription in virtually every country. It is included on the WADA (World Anti-Doping Agency) list of prohibited substances for athletic competition.
Research vials are not the approved pharmaceutical product, are not subject to the same manufacturing and purity controls, and their legal status varies significantly by jurisdiction.
This content is for educational purposes only. Not medical advice. Always consult a healthcare professional before starting any research protocol.
Reported protocol (research reference)
| Vial sizes | 10 mg |
|---|---|
| Reported dose | Beginners: 2-4 IU/day SC on an empty stomach or before sleep. Intermediate: 4-6 IU/day. 10 IU vial reconstituted with 1.0 mL BAC water = 10 IU/mL (≈3.3 mg/mL; 1 IU ≈ 0.33 mg). |
| Half-life | 3-5h IV; SC peak at 2-4h post-injection; elevated serum IGF-1 for 12-18h. |
| FDA status | FDA approved |